C Thomssen
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Möbus V, Kurbacher C, Untch M, Konecny G, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H, Jackisch C, AGO Breast Study Group (AGO-B). Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018; 29:178-185.
01.01.2018Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
01.01.2018Ann Oncol 2018; 29:178-185
Möbus V, Kurbacher C, Untch M, Konecny G E, Hinke A, Runnebaum I B, von Minckwitz G, Harbeck N, Huober Jens, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H J, Jackisch C, AGO Breast Study Group (AGO-B)
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober J, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol 2017; 28:1803-1810.
01.08.2017German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
01.08.2017Ann Oncol 2017; 28:1803-1810
Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober Jens, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H-J, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2017; 28:2899.
01.01.2017Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
01.01.2017Ann Oncol 2017; 28:2899
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates R, Kreipe H, Hartmann A, Pelz E, Erber R, Harbeck N. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 2016; 27:1035-1040.
18.02.2016Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
18.02.2016Ann Oncol 2016; 27:1035-1040
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober Jens, Peyro-Saint-Paul H, Kates R E, Kreipe H H, Hartmann A, Pelz E, Erber R, Harbeck N
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
Untch M, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Jackisch C, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd 2015; 75:556-565.
17.06.2015Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
17.06.2015Geburtshilfe Frauenheilkd 2015; 75:556-565
Untch M, Blohmer J-U, Costa S-D, Decker T, Diel I, Fasching P A, Fehm T, Janni W, Lück H-J, Maass N, Scharl A, Beckmann M W, Jackisch C, Thomssen C, Harbeck N, Huober Jens, von Minckwitz G, Gerber B, Kreipe H-H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
Deuker J, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann D, Rack B, Salat C, Sattler D, Tio J, von Abel E, Fischer D, Ober A, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer H, Conrad B, Feisel-Schwickardi G, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Christensen B, Burkamp U, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Ruhland F, Stefek A, Köhne C, Meinerz W, Grasshoff S, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Weder P, Steffens C, Lemster S, Schlag R, Müller T, von Minckwitz G, Nekljudova V, Gerber B, GBG/AGO-B study groups, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer J, Mau C, Potenberg J, Schilling J, Fehm T, Hauschild M, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J, Just M, Weiss E, Möbus V, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Khandan F, Kühn T, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kast K, Nestle-Krämling C, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Holms F. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372.
15.09.2014Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
15.09.2014Ann Oncol 2014; 25:2363-2372
Deuker J-U, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann D-M, Rack B, Salat C, Sattler D, Tio J, von Abel E, Fischer D, Ober A, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer H-U, Conrad B, Feisel-Schwickardi G, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Christensen B, Burkamp U, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Ruhland F, Stefek A, Köhne C-H, Meinerz W, Grasshoff S-T, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Weder P, Steffens C-C, Lemster S, Schlag R, Müller T, von Minckwitz G, Nekljudova V, Gerber B, GBG/AGO-B study groups, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer J-U, Mau C, Potenberg J, Schilling J, Fehm T, Hauschild M, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J U, Just M, Weiss E, Möbus V, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Khandan F, Kühn T, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kast K, Nestle-Krämling C, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Holms F
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober J, Kreipe H, Kates R, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol 2014; 25:1551-7.
14.05.2014Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
14.05.2014Ann Oncol 2014; 25:1551-7
Nitz U, Weiss E, Böhmer S, Kreienberg R, du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Hoffmann G, Augustin D, Möbus V, Gluz O, Huober Jens, Kreipe H H, Kates R E, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Kuhn W
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
Huober J, Nimmrich I, May C, Beckmann M, Baumgärtner A, Kubista E, Ragosch V, Azim H, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2011; 21:27-33.
08.09.2011Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
08.09.2011Breast 2011; 21:27-33
Huober Jens, Nimmrich I, May C, Beckmann M W, Baumgärtner A K, Kubista E, Ragosch V, Azim H A, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P A, Harbeck N
Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung
von Minkwitz G, Thomssen C, Schrauder M, Roller M, Rody A, Niederacher D, Müller M, Martin B, Loibl S, Lenhard M, Momor M, Karn T, Huober J, Harbeck N, Groner B, Eidtmann H, Kaufmann M. Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung. Geburtsh Frauenheilk 2008; 68:1160-1165.
01.01.2008Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung
01.01.2008Geburtsh Frauenheilk 2008; 68:1160-1165
von Minkwitz G, Thomssen C, Schrauder M, Roller M, Rody A, Niederacher D, Müller M, Martin B, Loibl S, Lenhard M, Momor M, Karn T, Huober Jens, Harbeck N, Groner B, Eidtmann H, Kaufmann M
Primäre und adjuvante Systemtheraphie des operablen Mammakarzinoms
Thomssen C, Huober J. Primäre und adjuvante Systemtheraphie des operablen Mammakarzinoms. Onkologe 2008; 14:504-513.
01.01.2008Primäre und adjuvante Systemtheraphie des operablen Mammakarzinoms
01.01.2008Onkologe 2008; 14:504-513
Thomssen C, Huober Jens